Correction to: The Impact of Obesity and Metabolic Surgery on Chronic Inflammation

Sonja Chiappetta¹ · Hannah M. Schaack¹ · Bettina Wölnerhanssen² · Christine Stier³ · Simone Squillante⁴ · Rudolf A. Weiner¹

Published online: 27 June 2018

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Correction to: Obesity Surgery

<https://doi.org/10.1007/s11695-018-3320-y>

In Table 4 the column labeled “*p* values” and its data should be deleted.

The online version of the original article can be found at <https://doi.org/10.1007/s11695-018-3320-y>

✉ Sonja Chiappetta
sonja1002@gmx.de

¹ Department of Obesity and Metabolic Surgery, Sana Klinikum Offenbach, 63069 Offenbach am Main, Germany

² Department of Clinical Research, St Claraspital, Basel, Switzerland

³ Adipositaszentrum, University Hospital of Würzburg, Würzburg, Germany

⁴ Ospedale del Mare, Naples, Italy

Table 4 Leukocyte count, C-reactive protein (CRP), HbA1c, liver enzymes (AST, ALT, GGT, bilirubin), and lipids (cholesterol, triglycerides) in different surgical groups: sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and one-anastomosis gastric bypass (OAGB)

		SG	RYGB	OAGB
Numbers	T0	241	159	68
	T1	208	138	61
	T3	121	109	40
	T6	87	88	18
Leukocytes [$\times 10^3/\mu\text{l}$]	T0	7.6 $\pm$ 2.1 [2.7–15.1]	7.3 $\pm$ 1.9 [2.3–15]	7.6 $\pm$ 1.9 [4.1–14.2]
	T1	6.5 $\pm$ 2.4 [2.7–16]	6.6 $\pm$ 1.6 [3.3–10.4]	6.9 $\pm$ 2 [3.7–11.9]
	T3	6.9 $\pm$ 2 [2.8–14]	6.7 $\pm$ 1.8 [3.5–11]	7 $\pm$ 1.4 [5.6–9.5]
	T6	7.1 $\pm$ 2.2 [3.2–12]	7.3 $\pm$ 1 [3.4–10.3]	7.1 $\pm$ 1.7 [5.2–10.4]
CRP [mg/l]	T0	11.7 $\pm$ 9.2 [4–99]	8.6 $\pm$ 5.4 [5–40]	10.6 $\pm$ 8.1 [5–39]
	T1	12.6 $\pm$ 15.8 [0.5–76]	7.4 $\pm$ 6.8 [1–34]	8.1 $\pm$ 10.5 [2–44]
	T3	7 $\pm$ 5.5 [0.4–23]	6.2 $\pm$ 4.9 [1–20]	7.1 $\pm$ 4.1 [5–16]
	T6	8.3 $\pm$ 12.1* [1–68.5]	5 $\pm$ 2.8* [1–14]	6 $\pm$ 2.7 [4–9]
HbA1c [%]	T0	5.9 $\pm$ 1.0 [4.6–10.2]	5.9 $\pm$ 1.0 [4.6–9.9]	6.7 $\pm$ 1.6 [4.6–11.6]
	T1	5.5 $\pm$ 0.7 [4.1–7.2]	5.7 $\pm$ 1.1 [4.5–9.3]	6.3 $\pm$ 1.2 [4.9–8.1]
	T3	5.7 $\pm$ 0.8 [4.5–8.3]	5.4 $\pm$ 0.5 [4.6–6.5]	5.8 $\pm$ 1.2 [4.6–7.6]
	T6	5.5 $\pm$ 0.5 [4.7–7.0]	5.5 $\pm$ 0.9 [4.6–8.1]	5.5 $\pm$ 0.7 [4.8–6.5]
HbA1c < 6.5 [%]	T0	5.5 $\pm$ 0.4 [4.6–6.4]	5.5 $\pm$ 0.4 [4.6–6.4]	5.6 $\pm$ 0.4 [4.6–6.4]
	T1	5.3 $\pm$ 0.5 [4.1–6.3]	5.3 $\pm$ 0.3 [4.6–6.1]	5.2 $\pm$ 0.4 [4.9–5.6]
	T3	5.4 $\pm$ 0.5 [4.5–7.1]	5.2 $\pm$ 0.4 [4.6–5.8]	5.0 $\pm$ 0.3 [4.6–5.4]
	T6	5.4 $\pm$ 0.4 [4.7–6.3]	5.1 $\pm$ 0.4 [4.6–6.1]	5. $\pm$ 0.2 [4.8–5.1]
HbA1c $\geq$ 6.5 [%]	T0	7.7 $\pm$ 1.1 [6.5–10.2]	7.6 $\pm$ 0.9 [6.5–9.9]	8.3 $\pm$ 1.5 [6.6–11.6]
	T1	6.4 $\pm$ 0.8 [5.5–7.2]	7.1 $\pm$ 1.5 [4.5–9.3]	7.0 $\pm$ 1.0 [5.6–8.1]
	T3	6.9 $\pm$ 0.9 [5.7–8.3]	5.9 $\pm$ 0.5 [5.1–6.5]	6.6 $\pm$ 0.84 [5.3–7.6]
	T6	5.7 $\pm$ 0.7 [5.2–7.0]	6.7 $\pm$ 1.2 [5.0–8.1]	6.2 $\pm$ 0.4 [5.9–6.5]
AST [U/l]	T0	35.8 $\pm$ 16.0 [13.0–119.0]	33.4 $\pm$ 15.6 [10.0–112.0]	38.8 $\pm$ 20.7 [13.0–109.0]
	T1	33.7 $\pm$ 20.1 [17.0–116.0]	31.1 $\pm$ 11.1 [16.0–69.0]	34.9 $\pm$ 13.2 [17.0–57.0]
	T3	26.2 $\pm$ 12.2 [13.0–89.0]	23.3 $\pm$ 6.3 [15.0–40.0]	27.3 $\pm$ 12.3 [14.0–53.0]
	T6	20.8 $\pm$ 6.3 [9.0–46.0]	22.4 $\pm$ 5.7 [13.0–42.0]	30.2 $\pm$ 18.7 [17.0–66.0]
ALT [U/l]	T0	46.4 $\pm$ 29.4 [12.0–196.0]	44.4 $\pm$ 41.7 [11.0–447.0]	48.2 $\pm$ 27.1 [11.0–126.0]
	T1	46.2 $\pm$ 31.7 [11.0–387.0]	42.8 $\pm$ 24.2 [14.4–113.0]	49.3 $\pm$ 26.6 [13.0–95.0]
	T3	29.7 $\pm$ 27.7 [10.0–211.0]	28.5 $\pm$ 10.6 [12.0–55.0]	33.1 $\pm$ 21.2 [11.0–83.0]
	T6	21.2 $\pm$ 11 [8.0–72.0]	24.7 $\pm$ 10.9 [10.0–55.0]	36.0 $\pm$ 23.4 [14.0–79.0]
GGT [U/l]	T0	46.4 $\pm$ 29.4 [12.0–196.0]	44.4 $\pm$ 41.7 [11.0–447.0]	48.2 $\pm$ 27.1 [11.0–126.0]
	T1	46.2 $\pm$ 31.7 [11.0–387.0]	42.8 $\pm$ 24.2 [14.4–113.0]	49.3 $\pm$ 26.6 [13.0–95.0]
	T3	29.7 $\pm$ 27.7 [10.0–211.0]	28.5 $\pm$ 10.6 [12.0–55.0]	33.1 $\pm$ 21.2 [11.0–83.0]
	T6	21.2 $\pm$ 11 [8.0–72.0]	24.7 $\pm$ 10.9 [10.0–55.0]	36.0 $\pm$ 23.4 [14.0–79.0]
Bilirubin [mg/l]	T0	0.5 $\pm$ 0.3 [0.1–1.5]	0.5 $\pm$ 0.3 [0.2–2.6]	0.6 $\pm$ 0.3 [0.2–1.6]
	T1	0.6 $\pm$ 0.2 [0.3–1.5]	0.5 $\pm$ 0.2 [0.2–1.2]	0.6 $\pm$ 0.2 [0.3–1.0]
	T3	0.6 $\pm$ 0.3 [0.2–1.4]	0.6 $\pm$ 0.2 [0.2–1.3]	0.5 $\pm$ 0.2 [0.2–0.8]
	T6	0.6 $\pm$ 0.2 [0.2–1.2]	0.6 $\pm$ 0.2 [0.3–1.4]	0.8 $\pm$ 0.2 [0.5–1.1]
Triglyceride [mg/dl]	T0	133.6 $\pm$ 63.6 [45.0–524.0]	132.7 $\pm$ 64.0 [46.0–511.0]	163.5 $\pm$ 93.0 [64.0–589.0]
	T1	122.5 $\pm$ 41.4 [43.0–241.0]	106.3 $\pm$ 29.3 [58.0–171.0]	132.2 $\pm$ 61.4 [69.0–254.0]
	T3	132.0 $\pm$ 47.8 [79.0–258.0]	105.5 $\pm$ 28.6 [44.0–205.0]	168.3 $\pm$ 53.1 [107.0–262.0]
	T6	121.6 $\pm$ 48.9 [60.0–265.0]	94.8 $\pm$ 31.6 [41.0–190.0]	97.5 $\pm$ 25.9 [53.0–123.0]

Table 4 (continued)

		SG	RYGB	OAGB
Cholesterol [mg/dl]	T0	182.0 ± 37.6 [107.0–300.0]	187.4 ± 36.4 [99.0–275.0]	183.8 ± 33.4 [117.0–277.0]
	T1	172.1 ± 42.5 [116.0–269.0]	159.2 ± 31.7 [91.0–240.0]	139.2 ± 30.2 [80.0–189.0]
	T3	193.2 ± 39.8 [125.0–285.0]	165.2 ± 26.7 [109.0–221.0]	169.1 ± 58.1 [102.0–253.0]
	T6	200.7 ± 42.7 [111.0–300.0]	169.3 ± 35.7 [81.0–229.0]	131.1 ± 30.9 [89.0–181.0]

Leukocyte count ($\times 10^3/\mu\text{l}$), C-reactive protein (CRP; mg/l), HbA1c, liver enzymes (AST: aspartate transaminase, ALT: alanine transaminase, GGT: gamma-glutamyltransferase), and lipids. Values are reported as mean $\pm$ standard deviation and range. T0 (preoperative), T1 (1 month postoperative), T3 (3 months postoperative), and T6 (6 months postoperative). One-way analysis of variance for comparisons among the SG, RYGB, and OAGB groups. Repeated measures one-way analysis of variance and post hoc Bonferroni test for differences among groups in preoperative (T0) and postoperative (T6).

* $p < 0.01$, repeated measures one-way analysis of variance and post hoc Bonferroni test